Pharming’s growth story leans on finding and treating more people with a very rare immune condition, but new research and genetic testing may take longer to turn into real patients than investors hope. With its older allergy medicine facing tougher competition and several big studies still years away, the next phase could hinge on whether the pipeline delivers on time.Read more
Pharming’s growth story leans on two rare-disease medicines: one that keeps serving the sickest patients, and another that’s quickly finding new patients and could soon be used in younger children. The upside depends on wider testing and diagnosis, while competition, trial setbacks, and pricing pushback could slow the momentum.Read more
Catalysts About Pharming Group Pharming Group is a commercial-stage biotech company focused on developing and marketing innovative therapies for rare and ultra-rare diseases. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
